research First-In-Human Clinical Trial Evaluating AI-09, A Novel Long-Lasting Ready-To-Use Liquid Injectable Neuromodulator For The Treatment Of Glabellar Lines
AI-09 is safe, effective, and reduces wrinkles for up to 6 months.
Search
forLearn
0 / 0 results — no results
Research
5 / 32 results
research Improvement in Scalp Hair Appearance Following Treatment With a Non-Ablative Fractional Laser: A Retrospective Observational Study
Non-ablative fractional laser treatment safely improves hair growth and scalp appearance.
research Clinical Response to Adjunctive Platelet-Rich Plasma Injections in a Patient with Alopecia Universalis on Oral Tofacitinib
A woman with severe hair loss saw significant hair regrowth after adding platelet-rich plasma injections to her treatment with tofacitinib.
research Objective Outcome Measures: Collecting Meaningful Data on Alopecia Areata
The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.
research Gene Variant in Amish a Clue to Better Aging
A genetic mutation linked to longer life and less disease was found in the Amish, and a drug is being developed to replicate these benefits.
Community Join
5 / 18 resultscommunity ET-02 Now Recruiting in Texas for Phase 1
Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.
community Eirion ET-02( RS 5441) managed to defeat rodents, finally
ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.
community Eirion Therapeutics Announces Potential Breakthrough Treatment for Hair Loss Based on First-in-Man Clinical Trial Results
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.
community Target Area Hair Count (TAHC) increase comparasion of all future treatments in clinical trial phases
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
community ICYMI: Eirion ET-02’s Successful Phase 1 Trial Results for Androgenic Alopecia Treatment
ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.